Ultrasound Can ID Breast Cancer Patients Who Need Lymph Nodes Removed
The investigators found that repeating ultrasound after chemotherapy could help to determine whether surgeons should remove only a few lymph nodes and test them for cancer, sparing patients whose sentinel nodes are cancer-free the removal of all nodes in the armpit, or take out all of the nodes.
“Our goal here is really to try to get away from, ‘Every patient with breast cancer needs these drugs, and this amount of chemotherapy and this surgery,’ and instead to personalise surgical treatment based on how the patient responds to chemotherapy,” said the study's lead author Judy C. Boughey, MD, a breast surgeon at Mayo Clinic in Rochester, NY.
In the past, when breast cancer was discovered to have spread to the lymph nodes under the arm, surgeons routinely removed all of them. However, taking out all of those lymph nodes may cause lymphoedema and limit the arm’s range of motion.
These days many breast cancer patients receive chemotherapy before surgery. Given improvements in chemotherapy drugs and increasing use of targeted therapy, surgeons are seeing more women whose cancer is eradicated from the lymph nodes by the time they reach the operating room, Dr. Boughey noted.
“That’s one of the really nice things about giving chemotherapy up front: It allows us to be less invasive with surgery, both in terms of breast surgery and lymph node surgery, and to tailor treatment based on response to chemotherapy,” she said.
Avoiding complete underarm lymph node removal when possible means fewer women will experience the complications that can result from that surgery, and avoiding those side effects should also save healthcare costs, the doctor added.
Most patients with lymph node-positive breast cancer receive radiation treatment after surgery. A new study is under way for men and women with breast cancer whose underarm lymph nodes are still positive for cancer after chemotherapy. The goal is to evaluate which is more effective: removing all of those nodes, or leaving the nodes and treating them with radiation, Dr. Boughey explained.
The current research was supported by National Cancer Institute grants U10 CA76001 to the American College of Surgeons Oncology Group, CA31946 to the Alliance for Clinical Trials in Oncology and CA33601 to the Alliance Statistics and Data Center.
Source: Mayo Clinic
Image Credit: Wikimedia Commons
Published on : Mon, 2 Feb 2015
Print as PDF
The SonoSite EDGE II is a high-resolution, all-digital, 9.0-pound (4.1 kg) ultrasound system with a 12.1in. LED full-bleed glass display. The Edge II boosts improvements in cardiac and abdominal image quality through DirectClear Technology and a new...
Wide high-resolution touch screen for easy ECG review Full-size keyboard with a durable cover keeping dust, dirt and liquids away, making it highly hygienic ETM Sport, the first automated interpretation of athletes’ ECGs based...
Introducing a new chapter in ultrasound visualization technology. X-Porte was developed from the ground up to incorporate a breakthrough, proprietary beam-forming technology: XDI (Extreme Definition Imaging). This signal analysis algorithm shapes...
Sectra PACS is designed for a high production environment with stability and usability in focus. Highlights include functions to speed up oncology workflows such as anatomical linking and support for reviewing complex multiparametric MRI studies such...
Sectra provides a complete solution for primary diagnostics in pathology. The solution includes archiving and storage solutions together with high-end review workstations. It allows pathologists to make their diagnoses and reports with higher precision...